Equities

Lantheus Holdings Inc

Lantheus Holdings Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)87.32
  • Today's Change0.87 / 1.01%
  • Shares traded1.48m
  • 1 Year change+28.19%
  • Beta0.4692
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Lantheus Holdings, Inc. is a radiopharmaceutical-focused company engaged in delivering science to enable clinicians to find, fight and follow disease to deliver patient outcomes. The Company classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Its Radiopharmaceutical Oncology diagnostics and therapeutic candidates help healthcare professionals (HCPs) find, fight, and follow cancer, with a focus in prostate cancer. Its pipeline also includes breast and other cancers. Its Precision Diagnostic products assist HCPs to find and follow diseases, with a focus in cardiology. Its Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma solutions platforms. Its commercial products include PYLARIFY, DEFINITY, Ga-DOTA-RM2, and others. Its pipeline includes B amyloid positron emission tomography (PET) imaging agent, NAV-4694, also known as F18-flutafuranol.

  • Revenue in USD (TTM)1.50bn
  • Net income in USD427.61m
  • Incorporated2007
  • Employees834.00
  • Location
    Lantheus Holdings Inc331 Treble Cove RdNORTH BILLERICA 01862United StatesUSA
  • Phone+1 (978) 671-8001
  • Fax+1 (302) 636-5454
  • Websitehttps://www.lantheus.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
LNTH:NMQ since
announced
Transaction
value
Meilleur Technologies IncDeal completed15 Jul 202415 Jul 2024Deal completed-29.25%--
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Envista Holdings Corp2.50bn-1.34bn3.68bn12.80k--1.20--1.47-7.77-7.7714.5117.860.41064.216.19195,570.30-21.931.94-25.272.3454.2057.65-53.425.291.773.130.31630.00-0.1012-2.04-142.10---4.22--
DENTSPLY SIRONA Inc3.90bn-413.00m3.71bn15.00k--1.49--0.9501-2.07-2.0718.9112.530.56412.945.91260,000.00-5.93-1.14-7.41-1.3252.1853.65-10.51-2.510.84443.210.471--1.10-0.107186.11---4.549.86
Guardant Health Inc692.26m-512.41m3.83bn1.78k------5.53-4.24-4.245.70-0.4880.4153.687.81389,126.50-30.72-22.26-35.19-24.5960.3164.62-74.02-97.075.85-8.041.06--25.4544.1426.76--0.2786--
ICU Medical Inc2.34bn-111.01m4.12bn14.00k--2.0236.201.76-4.57-4.5796.3183.760.53912.1613.94167,149.80-2.561.46-2.901.6532.8734.11-4.742.231.030.51580.43820.00-0.915410.0460.08---1.45--
Haemonetics Corporation1.36bn123.81m4.29bn3.66k35.484.9018.393.152.412.4126.4817.440.60011.877.02372,224.005.465.026.196.0754.0251.749.108.112.0927.430.58230.0012.016.231.8716.40-11.04--
Integer Holdings Corp1.68bn114.44m4.56bn10.50k41.892.8120.602.713.243.2247.8748.330.55944.935.14160,023.803.813.284.103.5327.0626.946.816.402.094.110.40280.0016.035.6238.719.3321.71--
Procept Biorobotics Corp199.84m-100.06m5.11bn626.00--20.42--25.55-1.95-1.953.894.630.50261.833.86319,238.00-25.16---28.58--57.39---50.07--5.07--0.1758--81.55---21.51------
Inspire Medical Systems Inc755.59m33.05m5.58bn1.01k171.118.01146.817.381.091.0925.1523.251.052.469.37747,372.904.60-11.275.12-12.6084.7784.474.37-13.576.94--0.00--53.1965.3252.87--148.37--
Stevanato Group SpA1.15bn120.12m5.94bn5.64k43.863.8729.385.190.44730.44734.265.070.52842.752.66203,340.605.54--7.39--29.20--10.48--1.2148.530.2148--10.34--1.95------
Lantheus Holdings Inc1.50bn427.61m6.07bn834.0014.515.1512.394.066.026.0221.0916.970.83838.285.091,794,723.0023.956.6932.767.7364.7857.5628.579.021.56--0.3240.0038.6530.441,063.8651.8135.48--
Merit Medical Systems Inc1.33bn120.04m6.12bn6.95k51.454.6228.114.622.042.0422.5522.710.63342.297.41190,772.805.732.456.322.7746.8344.509.053.913.8231.880.36190.009.247.3326.7015.86-11.16--
Glaukos Corp360.35m-149.57m7.77bn907.00--11.61--21.55-2.96-2.967.0612.130.38431.697.53397,295.50-15.95-8.73-17.23-9.3576.6174.77-41.51-28.694.71-311.240.1591--11.2611.66-35.75--14.44--
Repligen Corp622.64m-17.13m7.94bn1.78k--3.94154.7212.75-0.3079-0.307911.0936.000.2331.575.29349,206.40-0.64114.38-0.70325.0350.3755.43-2.7515.918.76--0.20550.00-20.3126.91-77.6420.1324.99--
Bruker Corp3.24bn304.90m8.52bn9.71k27.114.7218.052.632.072.0721.8911.920.65271.515.73333,913.706.128.388.1411.4049.3149.859.3811.390.708526.830.55499.8117.149.3644.0318.9116.794.56
Teleflex Inc3.03bn238.01m8.85bn14.50k37.801.9817.532.935.045.0364.0196.500.4042.116.76208,677.503.185.863.466.4255.9954.437.8714.621.396.610.281815.846.573.97-1.4712.732.510.00
Data as of Nov 21 2024. Currency figures normalised to Lantheus Holdings Inc's reporting currency: US Dollar USD

Institutional shareholders

45.67%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 30 Sep 20247.64m11.01%
The Vanguard Group, Inc.as of 30 Sep 20247.21m10.39%
Janus Henderson Investors US LLCas of 30 Sep 20243.54m5.10%
Farallon Capital Management LLCas of 30 Sep 20242.96m4.26%
SSgA Funds Management, Inc.as of 30 Sep 20242.52m3.63%
Fidelity Management & Research Co. LLCas of 30 Sep 20242.14m3.09%
Geode Capital Management LLCas of 30 Sep 20241.68m2.43%
Westfield Capital Management Co. LPas of 30 Sep 20241.52m2.19%
Dimensional Fund Advisors LPas of 30 Sep 20241.25m1.80%
Reinhart Partners, Inc.as of 30 Sep 20241.24m1.79%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.